Bulletin
Investor Alert

New York Markets Open in:

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

May 16, 2022, 8:03 a.m.

/zigman2/quotes/207821052/composite

$

48.56

Change

-0.04 -0.08%

Volume

Volume 238

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Previous close

$ 48.60

$ 48.60

Change

+6.00 +14.08%

Day low

Day high

$43.89

$48.97

Open

52 week low

52 week high

$38.85

$202.73

Open

Laura Sepp-Lorenzino

Currently, Laura Sepp-Lorenzino occupies the position of Chief Scientific Officer & Executive VP at Intellia Therapeutics, Inc. She is also on the board of Oligonucleotide Therapeutics Society, Inc., Alliance for Regenerative Medicine and Taysha Gene Therapies, Inc.

In her past career she was Executive Director & Head-RNA Therapeutics at Merck & Co., Inc., VP, Head-Nucleic Acid Therapies & Research at Vertex Pharmaceuticals, Inc. and Vice President of Alnylam Pharmaceuticals, Inc.

Dr. Sepp-Lorenzino received a graduate degree and a doctorate from New York University and an undergraduate degree from Universidad de Buenos Aires.

Transactions

Date Shares Transaction Value
08/30/2021 1,515   Disposition at $158.9 per share. 240,734
08/30/2021 3,932   Disposition at $157.77 per share. 620,352
08/30/2021 7,425   Disposition at $156.79 per share. 1,164,166
08/30/2021 16,115   Disposition at $155.61 per share. 2,507,656
08/30/2021 28,669   Disposition at $154.77 per share. 4,437,102
08/30/2021 20,645   Disposition at $153.64 per share. 3,171,898
08/30/2021 15,839   Disposition at $152.75 per share. 2,419,408
08/30/2021 70,000   Derivative/Non-derivative trans. at $14.25 per share. 997,500
08/30/2021 207   Disposition at $160.47 per share. 33,218
08/30/2021 2,653   Disposition at $159.64 per share. 423,525
08/30/2021 27,000   Derivative/Non-derivative trans. at $13.4 per share. 361,800
08/04/2021 126   Disposition at $141.63 per share. 17,846
08/04/2021 4,054   Disposition at $140.73 per share. 570,520
08/04/2021 2,772   Disposition at $139.85 per share. 387,665
08/04/2021 4,419   Disposition at $138.78 per share. 613,269
08/04/2021 6,344   Disposition at $137.72 per share. 873,696
08/04/2021 6,814   Disposition at $136.79 per share. 932,088
08/04/2021 1,471   Disposition at $135.47 per share. 199,277
08/04/2021 26,000   Derivative/Non-derivative trans. at $13.4 per share. 348,400

Officers and Executives

Dr. John M. Leonard
President, Chief Executive Officer & Director
Mr. Glenn Goddard
Treasurer, Chief Financial & Accounting Officer
Dr. Laura Sepp-Lorenzino
Chief Scientific Officer & Executive VP
Dr. Eliana Clark
Chief Technology Officer & Executive VP
Dr. David Lebwohl
Chief Medical Officer & Executive Vice President
Dr. Christine Foster
SVP-Business Development & Alliance Management
Mr. Derek Hicks
Chief Business Officer & Executive Vice President
Mr. Ian Karp
Senior Vice President-Corporate Communications
Ms. Marika St Amand
Chief Human Resources Officer
Mr. James Basta
Secretary, Executive VP & General Counsel
Dr. Frank A. G. M. Verwiel
Chairman
Mr. John Francis Crowley
Independent Director
Dr. Georgia Keresty
Independent Director
Ms. Muna Bhanji
Independent Director
Dr. Jean-Francois B. Formela
Independent Director
Ms. Caroline D. Dorsa
Independent Director
Dr. Jesse L. Goodman
Independent Director
Dr. Fred Ehrenkranz Cohen
Independent Director
Link to MarketWatch's Slice.